GlassScriptPhysician profile
Paul M Mansonhing
NPI 1649211079
$13,304.49
in general payments reported to CMS, 2019-2025
42 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,773 · 2020: $1,116 · 2021: $1,169 · 2022: $2,222 · 2023: $1,863 · 2024: $2,425 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,024.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,378.91 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $1,592.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,241.96 | 2019-2022 | |
| Lilly USA, LLC | $1,047.54 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $995.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.08 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $690.57 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $360.27 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Ardelyx, INC. | $282.68 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $275.00 | 2024 | Epclusa, Vemlidy |
| Amarin Pharma, INC. | $273.54 | 2019-2021 | |
| Corcept Therapeutics | $229.37 | 2024 | Korlym |
| Exact Sciences Corporation | $213.88 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $210.30 | 2019-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $206.42 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mansonhing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.